Program
lebrikizumab
Also written as “Lebrikizumab”, “lebrikizumab (MILR1444A)” and “LY3650150”.
Its studies are mostly in Dermatitis, Atopic · Asthma · Nasal Polyps · Rhinitis, Allergic, Perennial · Pulmonary Disease, Chronic Obstructive, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 194 open or running | phase 4since May 28, 2025 | Feb 16, 2018 | May 2027phase 3 · NCT06338995 |
| Hoffmann-La Roche | 180 open or running | phase 3since May 29, 2013 | Oct 27, 2008 | none ahead |
| Almirall | 63 open or running | phase 3since Nov 26, 2021 | Nov 26, 2021 | Apr 25, 2027phase 3 · NCT06526182 |
| Tanox | 10 open or running | phase 2since May 17, 2006 | May 17, 2006 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 31 studies since May 17, 2006.
- Sep 26, 2022Phase 3 study in Dermatitis, AtopicEli Lilly · NCT05559359 · 377 enrolled · United States, Argentina, Australia and more
- Feb 10, 2023Phase 3 study in Dermatitis, AtopicEli Lilly · NCT05735483 · 338 planned · United States, Argentina, Australia and more
- May 30, 2023Phase 3 study in Dermatitis, AtopicAlmirall · NCT05916365 · 174 enrolled · Germany, Poland
- Aug 7, 2023Phase 3 study in Dermatitis, AtopicAlmirall · NCT05990725 · 260 enrolled · Germany, Netherlands, United Kingdom
- Jan 29, 2024Phase 1 study in HealthyEli Lilly · NCT06243198 · 24 enrolled · China
- Feb 20, 2024Phase 3 study in Dermatitis, AtopicEli Lilly · NCT06280716 · 301 enrolled · China, South Korea
- Mar 25, 20242 phase 3 studiesEli Lilly · NCT06339008, NCT06338995
- Jul 24, 2024Phase 3 study in Dermatitis, AtopicAlmirall · NCT06526182 · 520 enrolled · Spain
- Apr 4, 2025Phase 3 study in Atopic Hand and Foot DermatitisEli Lilly · NCT06921759 · 221 enrolled · United States, Argentina, Australia and more
- May 28, 2025Phase 4 study in Dermatitis, AtopicEli Lilly · NCT07006792 · 233 enrolled · United States, Argentina, Brazil and more
- Apr 15, 2026Phase 3 study in DermatitisAlmirall · NCT07542483 · 270 planned · Germany
- Oct 8, 2026Phase 3 study in Dermatitis, AtopicAlmirall · NCT07873801 · 230 planned
- Oct 27, 2026Primary completion moved from 2026-09 to 2026-10-22Date moved laterphase 3 · +1 months · NCT06339008
- Nov 10, 2026Phase 2 study terminatedStudy stoppedNCT01987492 · “Sponsor decision to discontinue lebrikizumab development for the treatment of asthma.”
Ahead
- Apr 25, 2027Primary completion: phase 3 study in Dermatitis, AtopicAlmirall · NCT06526182
- May 2027Primary completion: phase 3 study in Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Eli Lilly · NCT06338995
- Dec 2027Primary completion: phase 3 study in Dermatitis, AtopicEli Lilly · NCT05735483
- Feb 2028Primary completion: phase 3 study in Dermatitis, AtopicAlmirall · NCT07873801
TargetBeta
“A humanized monoclonal antibody against interleukin 13 (IL-13) with immunosuppressive and anti-asthmatic activities”NCIt, by rule
“Interleukin-13 inhibitor; Interleukin-13 inhibitor”ChEMBL 37, by rule
Other programs on IL13
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| tilrekimig | Pfizer | phase 3 | 11 |
| lunsekimig | Sanofi | phase 3 | 10 |
| zumilokibart | AbbVie | phase 2 | 4 |
| ompekimig | Pfizer | phase 2 | 3 |
| GHZ339 | Novartis | phase 2 | 1 |
| ABBV-313 | AbbVie | phase 1 | 1 |
Studies
All 44 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07873801Dermatitis, Atopic | 3 | Not yet recruiting | Almirall | Feb 2028 | 230 |
| NCT07542483Dermatitis · Germany | 3 | Recruiting | Almirall | Aug 2028 | 270 |
| NCT07006792Dermatitis, Atopic · United States, Argentina, Brazil and more | 4 | Completed | Eli Lilly | May 14, 2026 | 233 |
| NCT06921759Atopic Hand and Foot Dermatitis · United States, Argentina, Australia and more | 3 | Completed | Eli Lilly | May 13, 2026 | 221 |
| NCT06526182Dermatitis, Atopic · Spain | 3 | Active, not recruiting | Almirall | Apr 25, 2027 | 520 |
| NCT06339008Rhinitis, Allergic, Perennial · United States, Belgium, China and more | 3 | Active, not recruiting | Eli Lilly | Oct 22, 2026 | 450 |
| NCT06338995Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) · United States, Argentina, Belgium and more | 3 | Recruiting | Eli Lilly | May 2027 | 510 |
| NCT06280716Dermatitis, Atopic · China, South Korea | 3 | Completed | Eli Lilly | Sep 25, 2025 | 301 |
| NCT06243198Healthy · China | 1 | Completed | Eli Lilly | Sep 3, 2024 | 24 |
| NCT05990725Dermatitis, Atopic · Germany, Netherlands, United Kingdom | 3 | Completed | Almirall | Jun 25, 2025 | 260 |
| NCT05916365Dermatitis, Atopic · Germany, Poland | 3 | Completed | Almirall | Apr 23, 2026 | 174 |
| NCT05735483Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | By invitation | Eli Lilly | Dec 2027 | 338 |
| NCT05559359Dermatitis, Atopic · United States, Argentina, Australia and more | 3 | Active, not recruiting | Eli Lilly | Jan 14, 2026 | 377 |
| NCT05372419Dermatitis, Atopic · United States | 3 | Completed | Eli Lilly | May 3, 2024 | 90 |
| NCT05369403Dermatitis, Atopic · United States | 3 | Completed | Eli Lilly | Jan 11, 2024 | 86 |
| NCT05149313Dermatitis, Atopic · Austria, Belgium, France and more | 3 | Completed | Almirall | Jan 30, 2023 | 331 |
| NCT04840901Healthy · United States | 1 | Completed | Eli Lilly | Feb 11, 2022 | 242 |
| NCT04760314Dermatitis, Atopic · Japan | 3 | Completed | Eli Lilly | Jul 31, 2022 | 286 |
| NCT04626297Dermatitis, Atopic · United States | 3 | Completed | Eli Lilly | Aug 3, 2022 | 254 |
| NCT04392154Dermatitis, Atopic · United States, Australia, Bulgaria and more | 3 | Completed | Eli Lilly | Jul 19, 2024 | 1,153 |
| NCT04250350Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Eli Lilly | Apr 20, 2022 | 206 |
| NCT04250337Dermatitis, Atopic · United States, Canada, Germany and more | 3 | Completed | Eli Lilly | Aug 11, 2021 | 228 |
| NCT04178967Dermatitis, Atopic · United States, Bulgaria, Canada and more | 3 | Completed | Eli Lilly | Jul 12, 2021 | 445 |
| NCT04146363Dermatitis, Atopic · United States, Australia, Canada and more | 3 | Completed | Eli Lilly | Jun 21, 2021 | 424 |
| NCT03443024Dermatitis, Atopic · United States | 2 | Completed | Eli Lilly | Feb 7, 2019 | 280 |
| NCT02546700Pulmonary Disease, Chronic Obstructive · United States, Argentina, Bulgaria and more | 2 | Completed | Hoffmann-La Roche | Nov 25, 2016 | 309 |
| NCT02546869Asthma | 3 | Withdrawn | Hoffmann-La Roche | Jun 29, 2016 | 0 |
| NCT02486809Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Oct 2015 | 176 |
| NCT02465606Dermatitis, Atopic · United States, Canada | 2 | Completed | Hoffmann-La Roche | May 30, 2016 | 55 |
| NCT02340234Dermatitis, Atopic · United States, Australia, Canada and more | 2 | Completed | Hoffmann-La Roche | Apr 2016 | 212 |
| NCT02104674Asthma · United States, Brazil, Bulgaria and more | 3 | Completed | Hoffmann-La Roche | Jan 22, 2016 | 313 |
| NCT02099656Asthma · United States, Canada, France and more | 2 | Completed | Hoffmann-La Roche | Oct 13, 2016 | 64 |
| NCT01987492Asthma · United States, Australia, Belgium and more | 2 | Terminated | Hoffmann-La Roche | Dec 19, 2016 | 230 |
| NCT01875003Asthma · United States, Argentina, Brazil and more | 3 | Terminated | Hoffmann-La Roche | Dec 28, 2016 | 346 |
| NCT01872689Idiopathic Pulmonary Fibrosis · United States, Australia, Belgium and more | 2 | Completed | Hoffmann-La Roche | Jul 28, 2017 | 505 |
| NCT01868061Asthma · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Jan 2, 2017 | 1,068 |
| NCT01867125Asthma · United States, Argentina, Australia and more | 3 | Completed | Hoffmann-La Roche | Dec 28, 2016 | 1,081 |
| NCT01545453Asthma · United States, Australia | 2 | Completed | Hoffmann-La Roche | Jul 2013 | 205 |
| NCT01545440Asthma · United States, Australia | 2 | Completed | Hoffmann-La Roche | Mar 2013 | 258 |
| NCT01423318Healthy Volunteer · United States | 1 | Completed | Hoffmann-La Roche | Feb 2012 | 60 |
| NCT00971035Asthma | 2 | Completed | Hoffmann-La Roche | Dec 2010 | 210 |
| NCT00930163Asthma | 2 | Completed | Hoffmann-La Roche | Jul 2010 | 218 |
| NCT00781443Asthma | 2 | Completed | Hoffmann-La Roche | Nov 2009 | 29 |
| NCT00441818Hodgkin Disease · United States | 2 | UNKNOWN | Tanox | 59 |
How it is read
Names in the registry
- “Lebrikizumab”, 37 entries
- “lebrikizumab”, 7 entries
- “lebrikizumab (MILR1444A)”, 5 entries
- “LY3650150”, 2 entries
- “TNX-650”, 1 entry
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 21 studies
- Asthma, 12 studies
- Nasal Polyps, 1 study
- Rhinitis, Allergic, Perennial, 1 study
- Pulmonary Disease, Chronic Obstructive, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.